Literature DB >> 15823602

Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production.

Chengwen Li1, R Jude Samulski.   

Abstract

One of the major limitations of the use of adeno-associated virus (AAV) as a tool for gene therapy is the difficulty in providing sufficient quantities of the virus for pre-clinical and clinical trials. Here, we report a novel approach for amplifying AAV helper functions, which mimics the normal replication of wild type (wt) AAV resulting in a high yield of AAV vectors. Cotransfection of replicating but non-packaging AAV helper constructs in the presence of adenovirus (Ad) produces a high level of Rep and Cap proteins. Yield of AAV2/GFP vector obtained from this helper DNA replication system was approximately 20-fold higher than traditional methods. Molecular analysis suggested that virus yield was associated with capsid protein production. The transfection ratio was optimized using these novel helper constructs, resulting in an additional 2-fold increase in vector yield without presence of replication competent AAV (rcAAV). This strategy supports development of AAV packaging systems that retain normal virus replication capability without helper virus encapsidation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823602     DOI: 10.1016/j.virol.2005.02.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Improved splicing of adeno-associated viral (AAV) capsid protein-supplying pre-mRNAs leads to increased recombinant AAV vector production.

Authors:  K David Farris; David J Pintel
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

2.  Adeno-Associated Virus Vector Mobilization, Risk Versus Reality.

Authors:  Liujiang Song; R Jude Samulski; Matthew L Hirsch
Journal:  Hum Gene Ther       Date:  2020-10       Impact factor: 5.695

3.  Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo.

Authors:  Chengwen Li; Matthew Hirsch; Aravind Asokan; Brian Zeithaml; Hong Ma; Tal Kafri; R Jude Samulski
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

4.  Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors.

Authors:  F Curtis Hewitt; Chengwen Li; Steven J Gray; Shelley Cockrell; Michael Washburn; R Jude Samulski
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

5.  Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer.

Authors:  Chengwen Li; Shuqing Wu; Blake Albright; Matthew Hirsch; Wuping Li; Yu-Shan Tseng; Mavis Agbandje-McKenna; Scott McPhee; Aravind Asokan; R Jude Samulski
Journal:  Mol Ther       Date:  2015-07-29       Impact factor: 11.454

6.  cis effects in adeno-associated virus type 2 replication.

Authors:  Peter Ward; Nathalie Clément; R Michael Linden
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

Review 7.  Controlled and localized genetic manipulation in the brain.

Authors:  Rachel Aronoff; C C H Petersen
Journal:  J Cell Mol Med       Date:  2006 Apr-Jun       Impact factor: 5.310

Review 8.  Molecular design for recombinant adeno-associated virus (rAAV) vector production.

Authors:  Juan Jose Aponte-Ubillus; Daniel Barajas; Joseph Peltier; Cameron Bardliving; Parviz Shamlou; Daniel Gold
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-04       Impact factor: 4.813

9.  Development of a Novel Recombinant Adeno-Associated Virus Production System Using Human Bocavirus 1 Helper Genes.

Authors:  Zekun Wang; Fang Cheng; John F Engelhardt; Ziying Yan; Jianming Qiu
Journal:  Mol Ther Methods Clin Dev       Date:  2018-10-04       Impact factor: 6.698

10.  A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy.

Authors:  Biao Dong; Andrea R Moore; Jihong Dai; Sean Roberts; Kirk Chu; Philipp Kapranov; Bernard Moss; Weidong Xiao
Journal:  Nucleic Acids Res       Date:  2013-05-15       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.